Allergic Rhinitis in Children and Adolescents

2019 ◽  
Vol 66 (5) ◽  
pp. 981-993 ◽  
Author(s):  
Charles Frank Schuler IV ◽  
Jenny Maribel Montejo
2010 ◽  
Vol 0 (0) ◽  
Author(s):  
Silvia M. A. Campanha ◽  
Maria J. F. Fontes ◽  
Paulo A. M. Camargos ◽  
Lincoln M. S. Freire (in memorian)

Author(s):  
Ricardo J. Saranz ◽  
Natalia A. Lozano ◽  
Alejandro Lozano ◽  
Graciela Alegre ◽  
Paula Robredo ◽  
...  

2018 ◽  
Vol 6 (5) ◽  
pp. 1752-1755.e3 ◽  
Author(s):  
Franklin Mariño-Sanchez ◽  
Meritxell Valls-Mateus ◽  
Oliver Haag ◽  
Isam Alobid ◽  
Jean Bousquet ◽  
...  

2015 ◽  
Vol 135 (2) ◽  
pp. AB270 ◽  
Author(s):  
Seo Hee Yoon ◽  
Yoon Hee Kim ◽  
Young A. Park ◽  
In Suk Sol ◽  
Min Jung Kim ◽  
...  

2012 ◽  
Vol 47 (11) ◽  
pp. 1070-1079 ◽  
Author(s):  
Jirina Chládková ◽  
Marian Senkerík ◽  
Zuzana Havlínová ◽  
Irena Krcmová ◽  
Jaroslav Chládek

Immunotherapy ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 227-239
Author(s):  
Li Xiang ◽  
Fengxia Liu ◽  
Lili Zhi ◽  
Weihong Jiang ◽  
Changshan Liu ◽  
...  

Aim: Multicenter study to investigate the safety of mite extract product Novo-Helisen Depot, Strengths 1 to 3 (NHD3), as subcutaneous immunotherapy (SCIT), in Chinese children and adolescents with allergic rhinitis (AR) and allergic asthma (AA). Patients & methods: We evaluated SCIT-related adverse events (AEs) during NHD3 14-week initial therapy in children (5–11 years) and adolescents (12–17 years) with perennial symptomatic AR and AA. Results: Among 3600 injections in 250 patients, 361/3600 (10.0%) injections caused SCIT-related AEs in 96/250 (38.4%) patients, 321/3600 injections (8.9%) caused local reactions in 89/250 (35.6%) and 40/3600 injections (1.1%) caused systemic reactions in 23/250 (9.2%). Conclusion: Initial SCIT treatment using NHD3 was safe and well tolerated in Chinese children and adolescents with AR and AA.


2020 ◽  
Vol 20 (2) ◽  
pp. 189-197
Author(s):  
Rasoul N. Kalmarzi ◽  
Pedram Ataee ◽  
Asadollah Fathollahpour ◽  
Masoud Behzadifar ◽  
Maryam Moradi ◽  
...  

Background: The prevalence of allergic rhinitis in the world is 10-15%, and it is currently the most common chronic disease among children. There is no comprehensive statistics about the prevalence of allergic rhinitis among Iranian children, therefore, this systematic review and metaanalysis was conducted to evaluate the prevalence of allergic rhinitis among the Iranian children. Methods: The present study was conducted based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. The data was collected using key words including allergic rhinitis, prevalence, epidemiology, child OR children, pediatrics and Iran, in international databases including PubMed, Scopus, Web of Science, Cochrane, Embase, and three national databases including Magiran, Iran Medex, and Scientific Information Databank (SID) till December 2018. The STROBE checklist was used for quality assessment. The data were analyzed using STATA software version 12.1. Results: The prevalence of allergic rhinitis in children and adolescents were 18% (99.7% CI: 10-28% with publication bias of 0.174) and 25% (99.8% CI: 17-33 with publication bias of 0.617) respectively. The prevalence of allergic rhinitis in males was estimated to be 27% (99.4% CI: 17-36) with publication bias of 0.538 and in females was 23% (99.4% CI: 14-31) with publication bias of 0.926. Conclusion: The prevalence of allergic rhinitis is approximately high among Iranian children and adolescents; thus, educational strategies should be considered to decrease the prevalence of this disease in Iran.


Sign in / Sign up

Export Citation Format

Share Document